Guillain-Barre Syndrome Market Size, Share & Trends Analysis Report by Therapeutics (Intravenous Immunoglobulin, Plasma Exchange), By Route of Administration, By Distribution Channel, And Region Forecasts, 2023 - 2030

Guillain-Barre Syndrome Market Trends

The global Guillain-Barre Syndrome (GBS) market size was valued at USD 610.5 million in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 4.77% from 2023 to 2030. Rising incidence of Guillain-Barre syndrome (GBS), specifically in regions with high rate of infectious diseases is anticipated to boost the market over the forecast period. Furthermore, the growing advancements in the diagnostic techniques, increasing R&D activities for novel treatments, and rising development in immunomodulatory therapies, which include intravenous immunoglobulin (IVIG) and plasmapheresis are further expected to drive the growth of the market.

A study conducted at the University of Minnesota in October 2023 stated that individuals with COVID-19 are at higher risk of developing GBS. Nearly 67% of patients already diagnosed with GBS were reported with indications related to respiratory or gastrointestinal infections during the six weeks leading up to their GBS diagnosis. Also, an average age of the GBS patients is 56 years irrespective of the gender and it is observed that nearly 50% of the patients are female.

According to the National Institute of Neurological Disorders and Stroke, the primary indicator of GBS typically involves muscle weakness. In more severe cases, the muscles responsible for breathing also weaken to the amount that external assistance for breathing becomes necessary. The most prominent stage of muscle weakness generally occurs within the initial two weeks following the onset of symptoms.

Therapeutics Insights

In 2022, the intravenous immunoglobulin segment dominated the market. Intravenous immunoglobulin (IVIG) contains antibodies collected from the blood of thousands of donors and is administered intravenously to help suppress the immune response that is attacking the peripheral nerves in GBS patients. By controlling the immune system, IVIG reduces the severity and period of the indications in some cases.

Plasma exchange is expected to grow at the fastest CAGR over the forecast period. Plasma exchange aims to eliminate the harmful antibodies and immune components from the patient's bloodstream, thereby reducing the autoimmune response responsible for GBS. By removing the harmful elements, plasma exchange helps to reduce GBS symptoms, stimulate nerve recovery, and recover the patient's overall diagnosis.

Route of Administration Insights

The parenteral route of administration dominated the market in 2022 and is expected to grow at the fastest CAGR over the forecast period. This includes methods such as intravenous (IV), intramuscular (IM), subcutaneous (SC), and intradermal injections. A parenteral route in GBS is rapid and reliable drug delivery to manage symptoms, such as pain relief, immunoglobulin therapy, or other medications which are required to lessen the immune system's overactive response. Thus, rapid drug delivery at the target area for immediate absorption is anticipated to fuel the market growth.

The oral route of administration is convenient, non-invasive, and easily accessible, as it involves pills, capsules, liquids, or other forms of medication. However, there are high risks of affecting the gastrointestinal system and the liver's metabolism of the administered substance and various side effects associated with the route.

Distribution Channel Insights

Hospital pharmacies dominated the market in 2022. GBS often requires specialized drugs, intravenous immunoglobulins, and close monitoring, which demands an efficient supply chain. Hospital pharmacists work in collaboration with various healthcare providers to ensure timely access to these medications.

Retail pharmacies are projected to grow at the fastest CAGR during the forecast period. Retail pharmacies ensure that individuals suffering from GBS have easy access to the required medications and equipment, acting as a vital driver of convenience and support in managing the condition. The easy accessibility of equipment and medications for GBS patients is projected to boost the segment growth over the forecast period.

Regional Insights

In 2022, North America dominated the market, owing to the increasing geriatric population, which increases the risk of developing GBS. Moreover, the growing R&D, as well as the presence of key major players and rising investments in various research, drive the growth of the market across the region. As of the 2021 census conducted by Statistics Canada, a total of approximately 7,021,430 individuals aged 65 years or older, with 3,224,680 being males and 3,796,750 being females. Thus, it is anticipated to propel the market growth in the near future in the region.

Asia Pacific is projected to grow with the fastest CAGR during the forecast period, owing to the growing geriatric population and increasing healthcare expenditure propelling the market in the region over the forecast period.

Key Guillain-Barre Syndrome Company Insights

The few key players in the global Guillain-Barre syndrome market comprise CSL Limited, Takeda Pharmaceutical Company Limited, Grifols S.A., Octapharma AG, and Kedrion Biopharma Inc among others.

• In April 2023, Hansa Biopharma enrolled for the Phase II trial of imlifidase in GBS. The company is expected to provide the data from the study in the second half of this year. This study was designed to evaluate the tolerability, safety, and effectiveness of imlifidase in arrangement with the standard of care (SoC) intravenous immunoglobulin (IVIg) in the treatment of GBS patients.

• In March 2022, Annexon Biosciences announced preclinical data at the AAN 2022 conference, which would support their complement inhibitor programs designed for the treatment of Guillain-Barré Syndrome and Huntington's Disease.